Cuprina Holdings (CUPR) Fair Value & Analysis
Healthcare · US · Market cap $11.7M
Cuprina Holdings
CUPR · US
Fair value as of: Jul 16, 2026
From 1 valuation models · updated 26 days ago
Fair value updated Jul 16, 2026, revised from $5.89 to $1.82 (−69.1%) since Jun 24, 2026. Share price −34.8% over the past month.
Below-average quality, and screening another 45% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($2.27). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($1.20 to $2.27) leaves room in how you read the outcome.
Price vs Fair Value (16 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
16‑month range $1.96 – $75.20 · fair‑value band $1.20 – $2.27 · the $3.32 price screens above the $1.82 fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Cuprina Holdings (CUPR) currently trades at $3.32, while our model-based Fair Value estimate is $1.82, implying the stock looks roughly 45.2% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $49.9K. Revenue grew 267.4% year over year. The balance sheet holds a net cash position of $2.6M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $1.20 (bear case) to $2.27 (bull case); at $3.32, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -45%, CUPR screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when CUPR reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds.
Full company description
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cuprina Holdings reported revenue of $49.9K in FY2025 versus $58.5K in FY2021, a compound −3.9%/yr. Reported net income was −$4.7M in FY2025.
CUPR screens 45% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Cuprina Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cuprina Holdings (CUPR) overvalued or undervalued?
What is the fair value of CUPR?
What is the quality score of CUPR?
What is the revenue of Cuprina Holdings (CUPR)?
What is the net profit margin of CUPR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cuprina Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.